# A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

> **NCT03432533** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 283 (actual)

## Conditions studied

- Post-Menopausal Osteoporosis

## Interventions

- **DRUG:** romosozumab HCP administration with PFS
- **DEVICE:** romosozumab self-administration with AI/Pen

## Key facts

- **NCT ID:** NCT03432533
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-06
- **Primary completion:** 2019-04-11
- **Final completion:** 2020-01-08
- **Target enrollment:** 283 (ACTUAL)
- **Last updated:** 2020-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03432533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03432533, "A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03432533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*